Total Payments
$3,788
2024 Payments
$334.37
Companies
16
Transactions
260
Medicare Patients
1,037
Medicare Billing
$174,668
Payment Breakdown by Category
Food & Beverage$3,556 (93.9%)
Education$232.39 (6.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,556 | 255 | 93.9% |
| Education | $232.39 | 5 | 6.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $709.75 | 50 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $694.93 | 62 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $657.92 | 35 | $0 (2024) |
| Allergan, Inc. | $649.78 | 60 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $309.85 | 12 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $193.96 | 11 | $0 (2019) |
| ITI, Inc. | $139.04 | 9 | $0 (2022) |
| Indivior Inc. | $115.35 | 5 | $0 (2024) |
| Alkermes, Inc. | $111.91 | 6 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.04 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $334.37 | 16 | Otsuka America Pharmaceutical, Inc. ($73.03) |
| 2023 | $512.93 | 24 | ABBVIE INC. ($229.87) |
| 2022 | $686.49 | 42 | ABBVIE INC. ($196.93) |
| 2021 | $401.82 | 26 | AbbVie Inc. ($213.55) |
| 2020 | $469.29 | 41 | Teva Pharmaceuticals USA, Inc. ($231.34) |
| 2019 | $634.35 | 54 | Allergan Inc. ($171.38) |
| 2018 | $471.27 | 40 | Allergan Inc. ($238.11) |
| 2017 | $277.49 | 17 | Vanda Pharmaceuticals Inc. ($89.11) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/23/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $23.68 | General |
| Category: Psychiatry/Psychology | ||||||
| 09/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: PSYCHIATRY | ||||||
| 06/25/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $29.01 | General |
| Category: BH | ||||||
| 06/17/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: Central Nervous System | ||||||
| 06/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: PSYCHIATRY | ||||||
| 05/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: PSYCHIATRY | ||||||
| 05/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: NEUROSCIENCE | ||||||
| 05/08/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: PSYCHIATRY | ||||||
| 03/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Insomnia | ||||||
| 02/23/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: PSYCHIATRY | ||||||
| 02/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Insomnia | ||||||
| 01/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: PSYCHIATRY | ||||||
| 01/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: PSYCHIATRY | ||||||
| 10/25/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.42 | General |
| Category: NEUROSCIENCE | ||||||
| 09/28/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: PSYCHIATRY | ||||||
| 09/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 255 | 782 | $112,238 | $44,687 |
| 2022 | 2 | 236 | 727 | $110,605 | $44,104 |
| 2021 | 2 | 249 | 865 | $128,445 | $49,346 |
| 2020 | 3 | 297 | 738 | $115,060 | $36,532 |
Total Patients
1,037
Total Services
3,112
Medicare Billing
$174,668
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 304 | $52,430 | $20,478 | 39.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 101 | 342 | $41,040 | $14,420 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 51 | $10,200 | $5,042 | 49.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 33 | 34 | $7,650 | $4,227 | 55.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Facility | 2023 | 13 | 51 | $918.00 | $520.11 | 56.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 150 | 507 | $83,005 | $33,676 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 71 | 205 | $24,600 | $9,303 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 15 | $3,000 | $1,125 | 37.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 185 | 763 | $113,725 | $43,722 | 38.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 71 | $8,520 | $3,785 | 44.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 31 | $6,200 | $1,838 | 29.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 172 | 515 | $81,655 | $26,522 | 32.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 76 | 169 | $20,280 | $5,161 | 25.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 41 | $8,200 | $3,258 | 39.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 13 | 13 | $4,925 | $1,590 | 32.3% |
About Joseph Poitier
Joseph Poitier is a Forensic Psychiatry healthcare provider based in North Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1003038738.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Joseph Poitier has received a total of $3,788 in payments from pharmaceutical and medical device companies, with $334.37 received in 2024. These payments were reported across 260 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($3,556).
As a Medicare-enrolled provider, Poitier has provided services to 1,037 Medicare beneficiaries, totaling 3,112 services with total Medicare billing of $174,668. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Forensic Psychiatry
- Other Specialties Child & Adolescent Psychiatry, Psychiatry
- Location North Miami, FL
- Active Since 05/03/2007
- Last Updated 06/03/2025
- Taxonomy Code 2084F0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003038738
Products in Payments
- VRAYLAR (Drug) $1,344
- AUSTEDO (Drug) $502.13
- ABILIFY MAINTENA (Drug) $409.11
- REXULTI (Drug) $211.19
- CAPLYTA (Drug) $206.08
- Fanapt (Drug) $193.96
- INVEGA SUSTENNA (Drug) $154.31
- SPRAVATO (Drug) $125.00
- ARISTADA (Drug) $99.34
- PERSERIS (Drug) $90.55
- ABILIFY ASIMTUFII (Drug) $49.36
- QUVIVIQ (Drug) $42.39
- INVEGA TRINZA (Drug) $30.54
- Austedo XR (Drug) $29.82
- SUBLOCADE (Drug) $24.80
- COBENFY (Drug) $23.68
- LATUDA (Drug) $22.02
- VYVANSE (Drug) $17.62
- NAMZARIC (Drug) $15.81
- Aristada 441 mg (Drug) $12.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.